NEJM March 12 2026 Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

This study investigates the effectiveness of the drug romiplostim in managing a frequent cancer treatment complication where chemotherapy causes a dangerous drop in blood platelets. By comparing the drug against a placebo in patients with gastrointestinal cancers, researchers aimed to see if the treatment could prevent dosage modifications like delays or reductions. The results demonstrated that patients receiving the drug were significantly more likely to maintain their intended chemotherapy schedule, showing a success rate more than double that of the control group. Ultimately, the findings suggest that this therapy is an efficacious solution for stabilizing platelet levels, allowing for more consistent and potentially more effective cancer treatment without introducing severe new safety risks.